Successful Outcome in Treating Ventriculitis with Intrathecal Colistin in a Child

AbdulAziz K. AlZailaie, MD* Ahmed A. Aljarie, MD** Hesham M. Abdelwahab, MD*** Ali A. Asiri, PharmD**** Ibrahim Alnaami, MD, MSc, FRCSC*****

CNS infections due to multi-resistant strains of Acinetobacter pose a serious complication in neurosurgical patients. The widespread use of antibiotics may have altered the epidemiology of post-neurosurgical CNS infections. Antimicrobial agents to which these strains are susceptible have poor central nervous system (CNS) penetration.

We report a case of a five-year-old female patient who was diagnosed with Juvenile Pilocytic Astrocytoma causing hydrocephalus. The tumor was surgically resected. During the procedure, an external ventricular drain (EVD) was inserted. Postoperatively, the patient developed ventriculitis and meningitis. Initially, systemic colistin was administered for four weeks with no improvement in the patient’s clinical condition, and the CSF cultures remained positive. Intrathecal colistin was then initiated as a last resort; the patient showed improvement clinically and cerebrospinal fluid (CSF) culture was negative on the fifth day of treatment.

THE CASE

A five-year-old female patient, not known to have any previous medical illness, presented with ataxic gait for two months. The patient was conscious, alert, oriented and vitally stable. Neurological examination revealed signs of cerebellar ataxia. Laboratory investigations were within normal. MRI with IV contrast of the head and neck revealed a large mass lesion (measuring 78x67x66 mm) related to the right cerebellar hemisphere and vermis encroaching on the fourth ventricle, see figures 1 and 2.

Bahrain Med Bull 2018; 40(1): 59 - 60

* Neurosurgical Resident
Department of Surgery
Aseer Central Hospital
Demonstrator, Najran University

** Infectious Disease Consultant

*** Pediatric Intensive Care Specialist
Abha Maternity and Children’s Hospital

**** Clinical Pharmacist
Intensive Care Unit
Aseer Central Hospital

***** Assistant Professor
Adult and Pediatric Neurosurgeon
Aseer Central Hospital
Director of Neurosurgery Training Program, King Khalid University
Kingdom of Saudi Arabia
E-mail: alza0002@gmail.com
The pathology of the lesion was Juvenile Pilocytic Astrocytoma (JPA). The tumor was surgically resected. During the procedure, an external ventricular drain (EVD) was inserted. Postoperatively, the patient developed meningitis and ventriculitis. CSF cultures were positive for Gram-negative bacilli (Acinetobacter MRAB). Initially, intravenous colistin was administered for four consecutive weeks, but there was no clinical improvement of the patient’s condition and CSF cultures remained positive. Failure to sterilize the CSF from Acinetobacter with intravenous colistin warranted the intrathecal administration. Colistin was administered intrathecally with a dose of 125,000 IU (10 mg)/day for three weeks. The patient showed improvement clinically, and the cerebrospinal fluid (CSF) culture was negative on the fifth day of treatment.

DISCUSSION

Karaiskos et al, in a review, found 81 patients (71 adults and 10 pediatrics) who received Colistin intrathecally for a median duration of 18.5 days. Four days is needed to achieve sterilization of cerebrospinal fluid. The rate of a successful outcome was 89%. Colistin toxicity revealed reversible chemical ventriculitis/meningitis in nine cases (11%)4.

The sterilization of CSF is reported in almost all treated patients with the use of intrathecal colistin1-4,6,7. Chemically induced meningeal irritation can cause treatment interruption, but irreversible toxicity has never been documented4,5.

In another study, 24 patients were identified where clinical and microbiological cure with IT/IVT colistin therapy rates were 83% and 92%, respectively; three patients (13%) developed chemical ventriculitis and one (4%) had treatment-associated seizures6. This convincing data led the team to initiate intrathecal colistin as the last therapeutic resort.

CONCLUSION

Our study shows that intrathecal colistin is an effective treatment option for MRAB CNS infection. To the best of our knowledge based on PubMed and other medical databases, it is one of the first few reported cases in pediatric population in English literature, and it is the first reported case in the Kingdom of Saudi Arabia. This case report and others reflect the potential safety and efficacy of intrathecal colistin in the management of MRAB CNS infection.

REFERENCES